Twenty accepted abstracts demonstrate growing clinical adoption and recognition of Cellvizio as a necessary tool for real-time optical biopsy in multiple gastrointestinal indications
Regulatory News:
Mauna Kea Technologies (Paris:MKEA) (OTCQX:MKEAY) (Euronext: MKEA, OTCQX: MKEAY/ MKEAF) inventor of Cellvizio®, the multidisciplinary confocal laser endomicroscopy (CLE) platform, today announced 20 abstracts supporting Cellvizio® to be presented at the Digestive Disease Week (DDW) Conference, being held on June 2-5 in Washington, D.C. These abstracts focus on Barrett’s esophagus, Inflammatory Bowel Disease / Syndrome (IBD / IBS), pancreatic cyst and other gastrointestinal diseases. This year marks a turning point for endomicroscopy with Cellvizio®, as studies are now focused on patient management, the technology having already proven its diagnostic performance in previous years.
“Real-time in vivo optical biopsy with Cellvizio is once again taking center stage at the Digestive Disease Week® as evidenced by the large number of high quality studies presented this year. Endomicroscopy is also been recognized as a key technology for the assessment of pancreatic diseases as Dr Krishna will present in his American Gastroenterological Association invited lecture on CLE.” said Sacha Loiseau, Ph.D., Founder and Chief Executive Officer of Mauna Kea Technologies. “We’re excited to see that most studies focus on demonstrating significant impact on patient management, positioning Cellvizio as a key driver for improved outcomes and reduced healthcare costs in multiple applications such as pancreatic lesions or Inflammatory Bowel Disease, two conditions in great need of better solutions. Our new sales team in the US will surely benefit from this strong momentum.”
Highlighted Featured Presentations:
Featured Poster Session:
You are also invited to visit us at booth #2145 in the Exhibit Hall.
Digestive Disease Week® (DDW)
Digestive Disease Week® (DDW)
is the largest international gathering of physicians, researchers and
academics in the fields of gastroenterology, hepatology, endoscopy and
gastrointestinal surgery. Jointly sponsored by the American Association
for the Study of Liver Diseases (AASLD), the American
Gastroenterological Association (AGA) Institute, the American Society
for Gastrointestinal Endoscopy (ASGE) and the Society for Surgery of the
Alimentary Tract (SSAT), DDW takes place June 2-5, 2018, at Walter E.
Washington Convention Center. The meeting showcases more than 5,000
abstracts and hundreds of lectures on the latest advances in GI
research, medicine and technology. More information can be found at www.ddw.org.
About Mauna Kea Technologies
Mauna Kea Technologies is a
global medical device company focused on eliminating uncertainties
related to the diagnosis and treatment of cancer and other diseases
thanks to real time in vivo microscopic visualization. The
Company’s flagship product, Cellvizio®, has received clearance/approval
in a wide range of applications in more than 40 countries, including the
United States, Europe, Japan, China, Canada, Brazil and Mexico. For more
information on Mauna Kea Technologies, visit www.maunakeatech.com
Disclaimer
This press release contains forward-looking
statements concerning Mauna Kea Technologies and its activities. Such
forward looking statements are based on assumptions that Mauna Kea
Technologies considers to be reasonable. However, there can be no
assurance that the anticipated events contained in such forward-looking
statements will occur. Forward- looking statements are subject to
numerous risks and uncertainties including the risks set forth in the
registration document of Mauna Kea Technologies registered by the French
Financial Markets Authority (Autorité des marchés financiers (AMF)) on
April 27, 2018 under number R.18-0429 and available on the Company's
website (www.maunakeatech.com),
and to the development of economic situation, financial markets, and the
markets in which Mauna Kea Technologies operates. The forward-looking
statements contained in this release are also subject to risks unknown
to Mauna Kea Technologies or that Mauna Kea Technologies does not
consider material at this time. The realization of all or part of these
risks could lead to actual results, financial conditions, performances
or achievements by Mauna Kea Technologies that differ significantly from
the results, financial conditions, performances or achievements
expressed in such forward-looking statements. This press release and the
information it contains do not constitute an offer to sell or to
subscribe for, or a solicitation of an order to purchase or subscribe
for, Mauna Kea Technologies shares in any country.
View source version on businesswire.com:
United States
The Ruth Group
Robert Flamm
/ Emma Poalillo
646-536-7017 / 7024
rflamm@theruthgroup.com
/ epoalillo@theruthgroup.com
or
U.S.
Media
The Ruth Group
Kirsten Thomas, 508-280-6592
kthomas@theruthgroup.com
or
France
and Europe
NewCap - Investor Relations
Tristan
Roquet Montégon, +33 (0)1 44 71 94 94
maunakea@newcap.eu